1.Preparation and evaluation of biodegradable molecularly imprinted polymers
Man LI ; Quanhong ZHU ; Minting LI ; Wenna WANG ; Jiaojiao DAI ; Yongguan YIN
Chinese Journal of Tissue Engineering Research 2013;(38):6817-6824
BACKGROUND:The cross-linking reagent is the main unit to support the skeleton of molecularly imprinted polymers, which is closely related to the bio-friendly adaption of polymers. The biocompatible and biodegradable capacities of common crosslinking agents are unclear.
OBJECTIVE:To prepare a novel biodegradable molecularly imprinted polymer and to evaluate the adsorption and biodegradability properties of the polymer.
METHODS:The biodegradable molecularly imprinted polymer was synthesized with the acrylated polyε-caprolactone as the cross-linking reagent under the UV polymerization. The adsorption of the polymer was evaluated by adsorption isotherm, Scatchard analysis and kinetic curves. The biodegradation of the polymer was observed in the simulated physiological environment system in vitro.
RESULTS AND CONCLUSION:Both the molecularly imprinted polymer and non-molecularly imprinted polymer showed an adsorption effect on theophyl ine, the template. But the adsorption amount of the molecularly imprinted polymer was significantly more than that of the non-molecularly imprinted polymer. The drug loading and encapsulation efficiency of the molecularly imprinted polymer were 1.54%and 12.48%, respectively. The degradation rates of molecularly imprinted polymer and poly(ε-caprolactone) diol were 6.60%and 1.33%, respectively, within the observation time in vitro. The obtained molecularly imprinted polymer not only exhibited specific adsorption to certain molecules but also showed good biodegradable properties in the simulated physiological environment system, which is necessary to be a potent drug carrier.
2.Hypercalcemia in pregnancy:One case report
Minting ZHU ; Lihao SUN ; Yulin ZHOU ; Yan LIU ; Wei ZHU ; Bei TAO ; Hongyan ZHAO ; Xi CHEN ; Jianmin LIU
Chinese Journal of Endocrinology and Metabolism 2016;32(5):415-417
[Summary] Hypercalcemia in pregnancy is a rare condition which brings considerable risks to mother and fetus. The most common cause is primary hyperparathyroidism(PHPT). The untypical symptoms and biochemical tests results add obstacles in the diagnosis of PHPT during pregnancy. The management is difficult, due to restrictions in choices of treatments and lack of clinical guidelines. Severity evaluation which takes consideration of calcium homeostasis during pregnancy is crucial for appropriate management. Parathyroidectomy during the second trimester is recommended for those with high serum calcium levels.
3.Effect of dibutyl phthalate and di-(2-ethylhexyl) phthalate on urine SOD activity and MDA content in rats.
Chijian ZHANG ; Mingming ZHANG ; Yuanming SUN ; Jianjun LI ; Minting FANG ; Xiaoxin ZHU ; Chunhong LIU
Journal of Southern Medical University 2012;32(2):160-164
OBJECTIVETo evaluate the effect of dibutyl phthalate (DBP) and di-(2-ethylhexyl) phthalate (DEHP) on urine superoxide dismutase (SOD) activity and malondialdehyde (MDA) content in rats.
METHODSAccording to 2×2 factorial analysis, 60 adult male SD rats were randomized into 10 groups (n=6), including a control group (fed with sesame oil), 3 DBP groups (fed with DBP at the doses of 30, 100 and 300 mg/kg), 3 DEHP groups (with DEHP at 50, 150, and 450 mg/kg), and 3 DBP+DEHP groups (with 30 mg/kg DBP+50 mg/kg DEHP, 100 mg/kg DBP+150 mg/kg DEHP, and 300 mg/kg DBP +450 mg/kg DEHP). The agents were administered in a single dose through gavage in a volume of 2 ml. After the treatments, the 24, 48, 72, and 96 h urine samples were collected to determine the SOD activity and MDA content.
RESULTSDBP and DEHP, either alone or in combination, significantly decreased SOD activity and increased MDA content in the urine collected at 24 h but not at the other time points. Such changes were gradually reversed with time.
CONCLUSIONDBP or DEHP treatment alone can result in significant oxidative damage in the kidney of rats, and the toxic effect of the combined exposure is even more obvious.
Animals ; Dibutyl Phthalate ; toxicity ; Diethylhexyl Phthalate ; toxicity ; Environmental Pollutants ; toxicity ; Kidney ; drug effects ; physiopathology ; Male ; Malondialdehyde ; urine ; Oxidative Stress ; drug effects ; Rats ; Rats, Sprague-Dawley ; Superoxide Dismutase ; metabolism ; urine
4.Study on the exocellular polysaccharide of Ureaplasma urealyticum biofilm in vitro
Minting HUANG ; Chun LU ; Guoxing ZHU ; Peiying FENG ; Wei LAI ; Xiaomin YE ; Feiyan LIN ; Jinfen ZHENG ; Han MA ; Meirong LI
Chinese Journal of Microbiology and Immunology 2012;32(4):335-339
Objective To investigate the extracellular polysaccharide distribution and components of Ureaplasma urealyticum (Uu) after biofilm having been developed in.Methods The standard serotype 3 and serotype 14 belong to biovar Parvo,and the standard serotype 4 and serotype 8 belong to biovar T960 were employed to form biofilrns in vitro.Scanning electron microscope and confocal laser scanning microscope were used to analysis the biofilms and extracellular polysaccharide.We used combination of two different labeled lectins,Canavalia ensiformis(FITC-ConA) and Erythrina cristagalli(ECA) which bind to specific polysaccharide residues to visualize extracellular polysaccharide in biofilms,and average uorescence intensity was evaluated Results All the strains can form the biofilmsin vitro.The biofilm was honeycomb-Like structures mainly,and extracellular polymeric substances accounts for majority of proportions.All the extracellular polysaccharide could be combined with FITC-ConA and ECA,and the total average fluorescence intensity of FITC-ConA was higher than ECA( P<0.001 ).Conclusion Ureaplasma urealyticum biofilm is honeycomb-like structures mainly.The extracellular polysaccharide contains,galactose,and N-acetyl glucan residual,and the glucose,mannose residual are the main components.
5.Introduction and reflection on the clinical practice guideline for the treatment of hypercalcemia of malignancy in adults
Yuying YANG ; Minting ZHU ; Lihao SUN ; Jianmin LIU
Chinese Journal of Endocrinology and Metabolism 2023;39(10):821-825
Hypercalcemia, a common metabolic complication of malignancies, often referred to as hypercalcemia of malignancy(HCM), is associated with a high incidence and mortality rate. In 2023, the American Society for Bone and Mineral Research and the European Society of Endocrinology released the Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. This guideline aimed to address key clinical issues related to adult HCM, refractory and recurrent hypercalcemia, hypercalcemia associated with calcitriol, and hypercalcemia caused by adult parathyroid cancer. This article provides an overview of this guideline and offers some suggestions for managing related conditions in China.